AstraZeneca (LON:AZN) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of £134.71 and traded as high as £140.80. AstraZeneca shares last traded at £140.76, with a volume of 214,151,109 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Citigroup started coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They set a “buy” rating and a £170 price target for the company. Deutsche Bank Aktiengesellschaft upped their price objective on shares of AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Berenberg Bank lifted their target price on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, Shore Capital Group restated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of £145.83.

AstraZeneca Trading Up 1.9%

The firm has a 50-day moving average of £143.94 and a 200 day moving average of £134.71. The company has a market cap of £218.28 billion, a P/E ratio of 21.52, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 60.87.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.